The page of DRREDDY. Captures the information on Price and Volume for the stock. It also contains the Live Stock Price and Volume, 52 Week High Low and Volume data.Intradaystock prediction for today 25-11-2024 is predicted based on technical analysis and should only be used as reference for learning purpose only.
Company Name | Price | Change | % Chg | Day High | Day Low | Previous Close | Volume |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Limited | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cipla Limited | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dr. Reddy's Laboratories Limited | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Divi's Laboratories Limited | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. It also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and manufacture of differentiated formulations for dermatology and neurology therapeutic areas. The company also engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2020, it had four late stage projects at various stages of development. The company's therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. It has collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists; and partnership with Department of Biotechnology - Biotechnology Industry Research Assistance Council for Sputnik V vaccine clinical trials in India. The company was founded in 1984 and is headquartered in Hyderabad, India.
Company | LTP | Change | Gain |
---|---|---|---|
State-Bank-of-India | 816.05 | 35.3 | 4.52 % |
Tata-Consultancy-Services-Limited | 4244.6001 | 171.75 | 4.22 % |
Company | LTP | Change | Loss |
---|---|---|---|
HDFC-Bank | 1745.6 | 4.4 | 0.25 % |
Axis-Bank-Limited | 1142.4 | 3.25 | 0.29 % |